3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Cytarabine
10
venetoclax
8
Rituximab
7
Daunorubicin
7
nilotinib
6
Azacitidine
6
blinatumomab
5
Bendamustine Hydrochloride
5
bosutinib
4
Imatinib Mesylate
4
obinutuzumab
3
asciminib
3
acalabrutinib
3
Mitoxantrone
3
Methotrexate
3
Etoposide
3
Dexamethasone
3
Decitabine
3
Dasatinib
3
zanubrutinib
2
trametinib
2
talquetamab
2
revumenib
2
pirtobrutinib
2
pegaspargase
2
ivosidenib
2
idelalisib
2
ibrutinib
2
fludarabine
2
decitabine and cedazuridine drug combination
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
umbralisib
×
Other hematologic neoplasm
×
Clear all
NCT02793583
2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3
Terminated
710 enrolled
1 FDA